---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-042506"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2026-09-14T13:28:02+00:00"
generated_at: "2026-09-14T13:29:06.663417+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology and Nerviano settle litigation, amend onvansertib license

## Summary
- Settlement resolves Cardiff v. Nerviano (Case No. 3:26-cv-03131-RBM-JLB) with mutual releases; no money exchanged
- Amended license adds exclusivity framework, additional license fee on annual net sales, and development milestones
- Nerviano gets board observer plus Scientific Advisory Board seat; revised post-termination royalty tiers added
- Revised assignment provision: Cardiff owes NMS percentage of proceeds if change of control before Phase III data readout
- Amendment effective upon dismissal with prejudice; existing license otherwise remains in force

## SEC filing metadata
- accession: 0001493152-26-042506
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2026-09-14T13:28:02+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000149315226042506/0001493152-26-042506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000149315226042506/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-042506
- JSON: https://secwatch.observer/filing/0001493152-26-042506.json
- Plain text: https://secwatch.observer/filing/0001493152-26-042506.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.